Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol

被引:115
作者
Kanebratt, K. P. [1 ,2 ]
Diczfalusy, U. [3 ]
Backstrom, T. [1 ]
Sparve, E. [1 ]
Bredberg, E. [4 ]
Bottiger, Y. [1 ]
Andersson, T. B. [2 ,5 ]
Bertilsson, L. [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Div Clin Pharmacol, Dept Lab Med, Huddinge, Sweden
[2] AstraZeneca R&D, Dept Dev DMPK & Bioanal, Molndal, Sweden
[3] Karolinska Univ Hosp, Karolinska Inst, Div Clin Chem, Dept Lab Med, Huddinge, Sweden
[4] AstraZeneca R&D, Dept Clin Pharmacol, Molndal, Sweden
[5] Karolinska Inst, Pharmacogenet Sect, Dept Physiol & Pharmacol, Stockholm, Sweden
基金
瑞典研究理事会;
关键词
D O I
10.1038/clpt.2008.132
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The Karolinska cocktail, comprising caffeine, losartan, omeprazole, and quinine, was given before and after administration of rifampicin (20, 100, or 500 mg daily) to measure induction of cytochrome P450 (P450) enzymes. rifampicin was given for 14 days to eight healthy subjects ( all of whom possessed at least one wild-type CYP2C9 and one wild-type CYP2C19 gene) in each dose group. 4 beta-hydroxycholesterol was assessed as an endogenous marker of CYP3A4 induction. a fourfold induction of CYP3A4 was seen at the highest dose by both quinine: 3'-hydroxyquinine and 4 beta-hydroxycholesterol measurements (P < 0.001). CYP3A4 was also induced at the two lower doses of rifampicin when measured by these two markers (P < 0.01 or P < 0.001). CYP1A2, CYP2C9, and CYP2C19 were induced after 500 mg rifampicin daily (1.2-fold, P < 0.05; 1.4-fold, P < 0.05; and 4.2-fold, P < 0.01, respectively). in conclusion, we have shown that the Karolinska cocktail and 4 beta-hydroxycholesterol can be used for an initial screening of the induction properties of a drug candidate.
引用
收藏
页码:589 / 594
页数:6
相关论文
共 33 条
[1]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :597-604
[2]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
TASSANEEYAKUL, W ;
TASSANEEYAKUL, W ;
MEYER, UA ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) :521-530
[3]   Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine [J].
Backman, JT ;
Granfors, MT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) :451-461
[4]   The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin [J].
Backman, JT ;
Kivistö, KT ;
Olkkola, KT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) :53-58
[5]   Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin [J].
Backman, JT ;
Olkkola, KT ;
Ojala, M ;
Laaksovirta, H ;
Neuvonen, PJ .
EPILEPSIA, 1996, 37 (03) :253-257
[6]   Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide [J].
Bidstrup, TB ;
Stilling, N ;
Damkier, P ;
Scharling, B ;
Thomsen, MS ;
Brosen, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (02) :109-114
[7]   Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans -: Evidence for involvement of cytochrome P450 3A4 [J].
Bodin, K ;
Bretillon, L ;
Aden, Y ;
Bertilsson, L ;
Broomé, U ;
Einarsson, C ;
Diczfalusy, U .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) :38685-38689
[8]   Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4 [J].
Bottiger, Ylva .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (08) :621-625
[9]   Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [J].
Chang, M ;
Dahl, ML ;
Tybring, G ;
Gotharson, E ;
Bertilsson, L .
PHARMACOGENETICS, 1995, 5 (06) :358-363
[10]   The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes [J].
Christensen, M ;
Andersson, K ;
Dalén, P ;
Mirghani, RA ;
Muirhead, GJ ;
Nordmark, A ;
Tybring, G ;
Wahlberg, A ;
Yasar, Ü ;
Bertilsson, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :517-528